Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Two-Drug shot beat the standard for shoulder pain?

NCT ID NCT06376981

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether adding hyaluronic acid to a standard corticosteroid injection works better for shoulder tendonitis pain than the steroid alone. About 132 adults with confirmed supraspinatus tendinopathy will receive either the combo or a placebo injection. Pain levels are checked at 1, 3, and 6 months to see which approach provides more relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyaluronic acid and corticosteroid injection
What this could lead to
If it works, this could offer a more effective injection for shoulder tendonitis pain, reducing the need for stronger treatments.
What could go wrong
This is a mid-stage trial with only 132 participants, so results may not apply to everyone. Adding hyaluronic acid may not provide extra benefit over the standard steroid shot.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active patient aged between 18 and 65; * Patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months; * Patient with simple tendinopathy or partial tendon rupture; * Patient with tendinopathy confirmed by ultrasound or MRI; * Patient with an active pain visual analog scale ≥ 4 for more than 6 weeks; * Patient with an active pain visual analog scale ≥ 4 on the day of inclusion; * Patient failing medical treatment (rest, analgesics, NSAIDs, physiotherapy); * Patient able to follow the protocol and having given oral informed consent to take part in the research; * Patient affiliated to the social security system or entitled person; Exclusion Criteria: * Patient suffering from a transfixing tendon rupture; * Patients suffering from post-traumatic tendon rupture; * Patients suffering from calcific tendinopathy (calcification \> 5 mm); * Patients with associated glenohumeral osteoarthritis; * Patients with associated symptomatic acromioclavicular osteoarthritis; * Patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronic inflammatory rheumatism, fibromyalgia, amyloidosis); * Patients who have had a subacromial infiltration in the previous 6 months; * Patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol); * Patients with a known allergy to lidocaine; * Patients with a local or generalised infection, or suspected infection; * Patients with severe coagulation disorders or taking anticoagulants; * Patients with severe and/or uncontrolled hypertension \> 160/100 mmHg; * Patients with unbalanced diabetes (last HbA1c \> 8.5%); * Patients with a history of addiction to psychoactive substances; * Patient participating in another clinical research protocol with an impact on the research objectives; * Patient already randomised in the study; * Patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception\* in the month prior to inclusion and up to 15 days after infiltration; * Patients under guardianship, curators or deprived of liberty; * Patient under a mandate for future protection activated ; * Patient under family guardianship ; * Patient under court protection ;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shoulder tendinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHD Vendée

    RECRUITING

    La Roche-sur-Yon, France

  • CHU Nantes

    RECRUITING

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.